(Reuters) - The split, expected to occur in the fourth quarter, calls
for each Abraxis shareholder to own one share of the hospital
products unit, Abraxis Pharmaceutical Products, and one share
of the new Abraxis BioScience for each share previously held.
Abraxis Pharmaceutical Products would be one of the largest
stand-alone public companies focused on injectable products,
according to the company.
Read more at Reuters.com Mergers News
for each Abraxis shareholder to own one share of the hospital
products unit, Abraxis Pharmaceutical Products, and one share
of the new Abraxis BioScience for each share previously held.
Abraxis Pharmaceutical Products would be one of the largest
stand-alone public companies focused on injectable products,
according to the company.
Read more at Reuters.com Mergers News
No comments:
Post a Comment